Controversial HIV vaccine strategy gets a second chance.
Jon
J
Cohen
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000293:Adolescent; D000328:Adult; D000818:Animals; D018849:Controlled Clinical Trials as Topic; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000628:therapy; D015497:HIV-1; D000882:Haplorhini; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D054547:National Cancer Institute (U.S.); D054579:National Institute of Allergy and Infectious Diseases (U.S.); D010919:Placebos; D013019:South Africa / Q000453:epidemiology; D013785:Thailand / Q000453:epidemiology; D014481:United States; D014611:Vaccination; D055815:Young Adult
D016915:AIDS Vaccines; D010919:Placebos